Last reviewed · How we verify
Standard: Aprepitant
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist.
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist. Used for Chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting, Postoperative nausea and vomiting.
At a glance
| Generic name | Standard: Aprepitant |
|---|---|
| Sponsor | CCTU |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
It works by blocking the action of substance P, a natural substance that causes nausea and vomiting. This is particularly useful in the treatment of chemotherapy-induced nausea and vomiting. By blocking the action of substance P, aprepitant reduces the incidence and severity of nausea and vomiting.
Approved indications
- Chemotherapy-induced nausea and vomiting
- Delayed chemotherapy-induced nausea and vomiting
- Postoperative nausea and vomiting
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Anxiety
Key clinical trials
- Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile (PHASE2)
- Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients (PHASE3)
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide (PHASE4)
- Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery (PHASE2)
- Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery. (PHASE4)
- Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard: Aprepitant CI brief — competitive landscape report
- Standard: Aprepitant updates RSS · CI watch RSS
- CCTU portfolio CI